Viking Therapeutics (LTS:0VQA) Pretax Margin %: % (As of Mar. 2026)


LTS:0VQA Viking Therapeutics Inc LTS:0VQA
26 GF Score
Price $39.04
! 3 Warning Signs
View Full Analysis

What is Viking Therapeutics Pretax Margin %?

Viking Therapeutics LTS:0VQA -4.43% 26 Pretax Margin % is % as of Mar. 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 26/100. The stock has 3 warning signs investors should review. Among 941 Biotechnology companies, Viking Therapeutics ranks worse than 106269.82% on this metric.

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Viking Therapeutics's Pre-Tax Income for the three months ended in Mar. 2026 was $-158.33 Mil. Viking Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Viking Therapeutics's pretax margin for the quarter that ended in Mar. 2026 was %.

The historical rank and industry rank for Viking Therapeutics's Pretax Margin % or its related term are showing as below:


LTS:0VQA's Pretax Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.42
* Ranked among companies with meaningful Pretax Margin % only.

Viking Therapeutics  (LTS:0VQA) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Viking Therapeutics Pretax Margin % Related Terms

Viking Therapeutics Pretax Margin % Historical Data

* Premium members only.

The historical data trend for Viking Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Pretax Margin % Chart

Viking Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Viking Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

LTS:0VQA vs EWTX, ACAD, DNLI: Pretax Margin % Comparison

For the Biotechnology subindustry, Viking Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viking Therapeutics Pretax Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viking Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Viking Therapeutics's Pretax Margin % falls into.


LTS:0VQA
26GF Score
Viking Therapeutics Inc LTS:0VQA
Pretax Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Viking Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Viking Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2025 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-359.639/0
= %

Viking Therapeutics's Pretax Margin for the quarter that ended in Mar. 2026 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-158.325/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Pretax Margin % →
What does a Pretax Margin % of % mean?
Viking Therapeutics (LTS:0VQA) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry.
Is Viking Therapeutics' Pretax Margin % too high?
Viking Therapeutics' current Pretax Margin % is %. Based on the distribution chart, Viking Therapeutics ranks #999999 out of 941 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Viking Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' Pretax Margin % compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #999999 out of 941 companies for Pretax Margin %. This places Viking Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current Pretax Margin % of %. The current Pretax Margin % is %. Viking Therapeutics' overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Viking Therapeutics Business Description

Address 9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
26GF Score

Get the complete analysis for LTS:0VQA

Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.04
Price